Models including pathological and radiomic features vs clinical models in predicting outcome of patients with metastatic non-small cell lung cancer treated with immunotherapy.
Nicolas Captier(Inserm), Emmanuel Barillot(Inserm), Clément Beaulaton(Institut Curie), Fanny Orlhac(Inserm), Marie Luporsi(Centre National de la Recherche Scientifique), Anne Vincent‐Salomon(Université Paris Sciences et Lettres), Hervé J. Brisse(Université Paris Sciences et Lettres), Marvin Lerousseau(Institut Curie), Christine Lonjou(Inserm), Irène Buvat(Centre National de la Recherche Scientifique), Nicolas Girard(Institut Curie), Sarah Lagha(Institut Curie), Paulette Salamoun Feghali(Institut Curie), Narinée Hovhannisyan(Institut Curie), Toulsie Ramtohul(Université Paris Sciences et Lettres), A. Tedesco(Institut Curie), Thomas Walter(European Molecular Biology Laboratory)
Cited by 1
Related Papers
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
|Cancer Cell|2018|1.7k
The Integrated Genomic Landscape of Thymic Epithelial Tumors
|Cancer Cell|2018|389
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2024|369
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
|Annals of Oncology|2020|313
METhodological RadiomICs Score (METRICS): a quality scoring tool for radiomics research endorsed by EuSoMII
|Insights into Imaging|2024|286